Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome

Launched by STEPHAN ELIEZ · Dec 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called transcranial alternating current stimulation (tACS) to see if it can help improve thinking skills in young people with 22q11.2 deletion syndrome, a genetic condition that can affect how the brain works. The researchers want to find out if this non-invasive technique, which involves applying a mild electrical current to the scalp, can enhance working memory and other cognitive functions. This is important because difficulties with thinking skills can be early signs of more serious mental health issues, and helping those at risk might prevent these problems from developing later.

To participate in this study, individuals need to be between 14 and 25 years old and have a confirmed diagnosis of 22q11.2 deletion syndrome. They must also be willing to take part and have consent from themselves or their caregivers. However, people with certain conditions like epilepsy, those who have deep brain stimulation devices, or those with significant brain injuries won't be eligible. Participants can expect to undergo several sessions of the tACS treatment, and the research team will monitor their progress to see how well the treatment works. This trial is currently recruiting participants, and everyone, regardless of gender, is welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed genetic diagnosis of 22q11DS
• • Age between 14 and 25 years old
• • Willingness to participate
• • Informed Consent signed by the subject and/or the caregiver(s)
• Exclusion Criteria:
• • Epilepsy
• • Deep brain stimulation electrodes
• • Traumatic brain injury
• • Facial metal implants